Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (2380)	3/9/2000 1:12:00 PM
From: Hank	Read Replies (1) \| Respond to of 5582

Call it what you will. I don't think it is gambling to bet against a company with unproven products that has never produced one iota of scientific evidence to back their claims. I think the fact that GUMM has traded nearly 50% off it's 52 high reflects that fact. All they have to do is stumble ONE more time, and the market will hammer them into the dust. I think next quarters earnings report will be the banana peel that will cause them to lose it. If they launch Ziscam in Europe and manage to hype their way back into the lime light down the road, it won't matter. I suspect I'll have a chance to cover with a comfortable profit long before then. If GUMM gives me the opportunity to make more money on the short side down the road, that's great. I'll be watching. As for the clinical trials being published, it's irrelevant. If they don't publish, nobody will be surprised (except you). If they do, it will be in another third rate journal and will be met with a brief day trader style rally followed by a long YAWWWNNNN.